270 related articles for article (PubMed ID: 32860965)
1. Comparative bioinformatics analysis of prognostic and differentially expressed genes in non-muscle and muscle invasive bladder cancer.
Silva TA; Azevedo H
J Proteomics; 2020 Oct; 229():103951. PubMed ID: 32860965
[TBL] [Abstract][Full Text] [Related]
2. Extracellular matrix-related genes play an important role in the progression of NMIBC to MIBC: a bioinformatics analysis study.
Zhang H; Shan G; Song J; Tian Y; An LY; Ban Y; Luo GH
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32391563
[TBL] [Abstract][Full Text] [Related]
3. Dynamic expression changes between non-muscle-invasive bladder cancer and muscle-invasive bladder cancer.
Zhao YG; Shi BY; Qian YY; Bai HW; Xiao L; He XY
Tumori; 2014; 100(6):e273-81. PubMed ID: 25688510
[TBL] [Abstract][Full Text] [Related]
4. Identification of prognostic biomarkers associated with stromal cell infiltration in muscle-invasive bladder cancer by bioinformatics analyses.
Li P; Cao J; Li J; Yao Z; Han D; Ying L; Wang Z; Tian J
Cancer Med; 2020 Oct; 9(19):7253-7267. PubMed ID: 32786144
[TBL] [Abstract][Full Text] [Related]
5. Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing.
Wang F; Dong X; Yang F; Xing N
Front Genet; 2022; 13():831146. PubMed ID: 35419031
[No Abstract] [Full Text] [Related]
6. Prognostic Implications of Immunohistochemical Biomarkers in Non-muscle-invasive Blad Cancer and Muscle-invasive Bladder Cancer.
Boegemann M; Krabbe LM
Mini Rev Med Chem; 2020; 20(12):1133-1152. PubMed ID: 27173513
[TBL] [Abstract][Full Text] [Related]
7. A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer.
Piao XM; Kang HW; Jeong P; Byun YJ; Lee HY; Kim K; Seo SP; Kim WT; Lee JY; Ha YS; Choi YH; Moon SK; Yun SJ; Kim WJ
Urol Oncol; 2021 Apr; 39(4):237.e21-237.e29. PubMed ID: 33339725
[TBL] [Abstract][Full Text] [Related]
8. Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion.
Franco R; Zappavigna S; Gigantino V; Luce A; Cantile M; Cerrone M; Facchini G; Perdonà S; Pignata S; Di Lorenzo G; Chieffi S; Vitale G; De Sio M; Sgambato A; Botti G; Yousif AM; Novellino E; Grieco P; Caraglia M
J Exp Clin Cancer Res; 2014 Jun; 33(1):48. PubMed ID: 24893613
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer Progression.
Piao XM; You C; Byun YJ; Kang HW; Noh J; Lee J; Lee HY; Kim K; Kim WT; Yun SJ; Lee SC; Kang K; Kim YJ
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884561
[TBL] [Abstract][Full Text] [Related]
10. The role of TAp63γ and P53 point mutations in regulating DNA repair, mutational susceptibility and invasion of bladder cancer cells.
Wang HT; Lee HW; Weng MW; Liu Y; Huang WC; Lepor H; Wu XR; Tang MS
Elife; 2021 Nov; 10():. PubMed ID: 34747697
[TBL] [Abstract][Full Text] [Related]
11. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
[TBL] [Abstract][Full Text] [Related]
12. Integrative Multi-Omics Analysis for the Determination of Non-Muscle Invasive vs. Muscle Invasive Bladder Cancer: A Pilot Study.
Yu EY; Zhang H; Fu Y; Chen YT; Tang QY; Liu YX; Zhang YX; Wang SZ; Wesselius A; Li WC; Zeegers MP; Xu B
Curr Oncol; 2022 Jul; 29(8):5442-5456. PubMed ID: 36005168
[TBL] [Abstract][Full Text] [Related]
13. The evolution of bladder cancer genomics: What have we learned and how can we use it?
Audenet F; Attalla K; Sfakianos JP
Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
[TBL] [Abstract][Full Text] [Related]
14. High S100A7 expression is associated with early muscle invasion and poor survival in bladder carcinoma.
Dong Y; Zhu GY; Hao L; Liang Q; Zhou JH; Shi ZD; Yu H; Ma WM; Fan T; Zhang WD; Zang GH; Han CH
Ann Diagn Pathol; 2022 Feb; 56():151847. PubMed ID: 34742033
[TBL] [Abstract][Full Text] [Related]
15. Novel Ferroptosis-Related Multigene Prognostic Models for Patients with Bladder Cancer.
Zhang S; Wang C; Xia W; Duan H; Qian S; Shen H
Int J Gen Med; 2021; 14():8651-8666. PubMed ID: 34849009
[TBL] [Abstract][Full Text] [Related]
16. Identification of an immunotherapy-responsive molecular subtype of bladder cancer.
Song BN; Kim SK; Mun JY; Choi YD; Leem SH; Chu IS
EBioMedicine; 2019 Dec; 50():238-245. PubMed ID: 31735557
[TBL] [Abstract][Full Text] [Related]
17. Utility of SAM68 in the progression and prognosis for bladder cancer.
Zhang Z; Yu C; Li Y; Jiang L; Zhou F
BMC Cancer; 2015 May; 15():364. PubMed ID: 25944080
[TBL] [Abstract][Full Text] [Related]
18. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
[TBL] [Abstract][Full Text] [Related]
19. Bladder cancer invasion predictability based on preoperative neutrophil-lymphocyte ratio.
Kaynar M; Yıldırım ME; Badem H; Caviş M; Tekinarslan E; Istanbulluoğlu MO; Karataş ÖF; Çimentepe E
Tumour Biol; 2014 Jul; 35(7):6601-5. PubMed ID: 24696263
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of cadherin-11 for subsequent recurrence and progression in non-muscle invasive bladder cancer.
Chen MK; Chen ZJ; Xiao KH; Qin ZK; Ye YL; Wen WJ; Bian J; Xue KY; Zhou QZ; Guo WB; Zhou JH; Xia M; Li X; Liu CD
Jpn J Clin Oncol; 2020 Apr; 50(4):456-464. PubMed ID: 31894237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
